Ventripoint Diagnostics Ltd. Seeks Approval to Extend Private Placement

Toronto, Ontario — October 30, 2026 — Leads & Copy — Ventripoint Diagnostics Ltd. announced its intention to seek approval from the TSX Venture Exchange to extend a previously announced non-brokered private placement. The offering, aiming to raise up to $350,000 through the sale of 3,500,000 units at $0.10 per unit, had its first tranche close on September 8, 2026.

Each unit comprises one common share and one common share purchase warrant. Each warrant grants the holder the right to purchase one common share at $0.14 for 24 months following the closing of the offering. Ventripoint retains the option to accelerate the warrant expiry if its common shares trade at $0.30 for 10 consecutive trading days, with 30 days' notice provided.

Proceeds from the offering are earmarked for commercialization efforts, the advancement of Ventripoint's core diagnostic technology platform, and general working capital. All securities issued under the offering will be subject to a statutory hold period of four months plus one day from the closing date. The offering is contingent on the final approval of the TSX Venture Exchange.

The securities are not registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities, nor will there be any sale in any jurisdiction where such offer, solicitation, or sale would be unlawful.

Ventripoint Diagnostics Ltd. is recognized as a leader in applying artificial intelligence to echocardiography. Its VMS+ products utilize proprietary knowledge-based reconstruction technology, developed over a decade, to deliver cardiac measurements comparable in accuracy to MRI. This affordable alternative aims to provide cardiologists with increased confidence in patient management. The company's products are designed to improve patient care and guide future development. The VMS+ system is compatible with all ultrasound systems from any vendor and has received regulatory market approval in the U.S., Europe, and Canada.

Source: Ventripoint Diagnostics Ltd.